Sanofi Pasteur's Quadrivalent Influenza mRNA Vaccine MRT5413 is positioned to compete in the growing influenza vaccine market, particularly as mRNA technology gains traction following its success in COVID-19 vaccines. The study's focus on safety and immunogenicity across various dose levels may provide a competitive edge in terms of efficacy and safety profile. With an enrollment of 682 participants and a completion date set for April 2024, the results could influence market dynamics significantly, especially if the vaccine demonstrates superior performance compared to existing standard and high-dose influenza vaccines. The potential for expanded use in older populations (≥65 years) also opens avenues for market penetration in a demographic that is particularly vulnerable to influenza.